title: Clinical evolution of substance use disorder patients during treatment with quetiapine: a 12-week, open-label, naturalistic trial.
abstract: OBJECTIVE
  Substance use disorders (SUDs) are associated with a variety of psychiatric disorders and mood and behavioral instability. Growing evidence suggests that the atypical antipsychotic quetiapine may be useful in the treatment of SUDs. The primary objective of the current open-label trial was to examine the effects of quetiapine on SUD outcomes in patients entering detoxification.
  
  
  METHODS
  Thirty-three nonpsychosis SUD patients participated. Patients received quetiapine for a 12-week beginning in detoxification. Craving, quantities used and psychiatric symptoms were evaluated on baseline and at end point.
  
  
  RESULTS
  Out of 33 recruited patients, 26 completed > 9 weeks of treatment. Last observation carried forward (LOCF) analyses revealed that craving, SUD severity and quantities used improved during the study. Psychiatric and depressive symptoms also improved.
  
  
  CONCLUSIONS
  Our results cannot be attributed per se to the pharmacological effects of quetiapine owing to the open-label design of the study, the small sample size involved and the fact that patients were involved in an intensive therapy program. Nevertheless, our results indicate that quetiapine may be helpful for the treatment of SUD patients entering detoxification. Controlled studies are warranted to determine whether these results are quetiapine-related.
authors.affiliation: University of Montreal, Fernand-Seguin Research Center, Department of Psychiatry, Hochelaga, Montreal, Canada.
authors.forename: Elie
authors.initials: E
authors.lastname: Rizkallah
authors.forename: Emmanuel
authors.initials: E
authors.lastname: Stip
authors.forename: Simon
authors.initials: S
authors.lastname: Zhornitsky
authors.forename: Tania
authors.initials: T
authors.lastname: Pampoulova
authors.forename: Alain
authors.initials: A
authors.lastname: Gendron
authors.forename: Pierre-Paul
authors.initials: PP
authors.lastname: Rompré
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Chiasson
authors.forename: Stéphane
authors.initials: S
authors.lastname: Potvin
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000494:pharmacology*; D003987:Dibenzothiazepines / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D000069348:Quetiapine Fumarate; D012107:Research Design; D012720:Severity of Illness Index; D019966:Substance-Related Disorders / Q000188:drug therapy* / Q000534:rehabilitation; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate